Merck KGaA’s Oncology Sales And Pipeline Updates Dominate Q3 Earnings
Bavencio Sees Double-Digit Growth
The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.
You may also be interested in...
Merck KGaA calls for data on Indian firm Enzene’s biosimilar cetuximab to be made available in the public domain, citing the Helsinki Declaration.
The German firm is eyeing licensing opportunities in 2023 to fill up its mid-stage pipeline.
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.